In the past week, RIGL stock has gone down by -13.73%, with a monthly decline of -19.41% and a quarterly plunge of -21.47%. The volatility ratio for the week is 4.54%, and the volatility levels for the last 30 days are 6.71% for Rigel Pharmaceuticals. The simple moving average for the past 20 days is -15.89% for RIGL’s stock, with a 1.09% simple moving average for the past 200 days.
Is It Worth Investing in Rigel Pharmaceuticals (NASDAQ: RIGL) Right Now?
The 36-month beta value for RIGL is also noteworthy at 0.95. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for RIGL is 171.92M, and at present, short sellers hold a 2.88% of that float. The average trading volume of RIGL on April 01, 2024 was 1.10M shares.
RIGL) stock’s latest price update
Rigel Pharmaceuticals (NASDAQ: RIGL)’s stock price has gone decline by -17.23 in comparison to its previous close of 1.48, however, the company has experienced a -13.73% decrease in its stock price over the last five trading days. Seeking Alpha reported 2024-03-05 that Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q4 2023 Earnings Conference Call March 5, 2024 4:30 AM ET Company Participants Ray Furey – Executive Vice President, General Counsel and Corporate Secretary Raul Rodriguez – President and Chief Executive Officer Dave Santos – Chief Commercial Officer Francois Di Trapani – Senior Vice President of Medical Affairs Dean Schorno – Chief Financial Officer Conference Call Participants Yigal Nochomovitz – Citigroup Kristen Kluska – Cantor Fitzgerald Kalpit Patel – B. Riley Securities Operator Greetings and welcome to Rigel Pharmaceuticals Financial Conference Call for the Fourth Quarter and Full Year 2023.
Analysts’ Opinion of RIGL
Many brokerage firms have already submitted their reports for RIGL stocks, with Piper Sandler repeating the rating for RIGL by listing it as a “Neutral.” The predicted price for RIGL in the upcoming period, according to Piper Sandler is $2 based on the research report published on April 03, 2023 of the previous year 2023.
Piper Sandler gave a rating of “Neutral” to RIGL, setting the target price at $1 in the report published on June 08th of the previous year.
RIGL Trading at -8.36% from the 50-Day Moving Average
After a stumble in the market that brought RIGL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.50% of loss for the given period.
Volatility was left at 6.71%, however, over the last 30 days, the volatility rate increased by 4.54%, as shares sank -17.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.10% lower at present.
During the last 5 trading sessions, RIGL fell by -9.51%, which changed the moving average for the period of 200-days by -19.69% in comparison to the 20-day moving average, which settled at $1.4433. In addition, Rigel Pharmaceuticals saw -15.52% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RIGL starting from RODRIGUEZ RAUL R, who sale 30,545 shares at the price of $1.14 back on Feb 05 ’24. After this action, RODRIGUEZ RAUL R now owns 2,036,629 shares of Rigel Pharmaceuticals, valued at $34,821 using the latest closing price.
Santos David A, the EVP, Chief Commercial Officer of Rigel Pharmaceuticals, sale 8,918 shares at $1.14 during a trade that took place back on Feb 05 ’24, which means that Santos David A is holding 349,093 shares at $10,167 based on the most recent closing price.
Stock Fundamentals for RIGL
Current profitability levels for the company are sitting at:
- -0.18 for the present operating margin
- 0.94 for the gross margin
The net margin for Rigel Pharmaceuticals stands at -0.22. The total capital return value is set at -0.32.
Based on Rigel Pharmaceuticals (RIGL), the company’s capital structure generated 1.9 points at debt to capital in total, while cash flow to debt ratio is standing at -0.09. The debt to equity ratio resting at -2.11. The interest coverage ratio of the stock is -2.98.
Currently, EBITDA for the company is -16.98 million with net debt to EBITDA at -1.61. When we switch over and look at the enterprise to sales, we see a ratio of 2.03. The receivables turnover for the company is 3.83for trailing twelve months and the total asset turnover is 1.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.86.
Conclusion
In summary, Rigel Pharmaceuticals (RIGL) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
